A microbiological report supports release of an incoming food hydrocolloid lot when the sampling plan, analytical method, test portion and reporting capability meet the agreed requirements, and the results comply. Check whether the report can resolve the acceptance criterion before interpreting a low result. “<100 CFU/g” cannot establish compliance with a limit of 10 CFU/g. For a qualitative pathogen test, “not detected” needs the organism, analytical mass and method. Gum powders also require attention to material-specific preparation, because the prescribed procedure may include steps intended to control thickening or gelling.

This review is for QA/QC assessment of dry food-use hydrocolloid powders, including xanthan gum, guar gum and declared gum blends. It evaluates evidence against agreed microbiological requirements. It does not establish common acceptance limits or determine the overall safety of a finished food.

Check Whether the Report Can Answer the Specification

Place the requirement beside the reported result. Identify the microbial group or organism, acceptance criterion, method and edition, analytical portion, and sampling plan.

For enumeration, CFU/g means colony-forming units per gram. Preserve qualifiers such as “less than” or “estimated”: they affect what the reported number can establish.

Consider an illustrative requirement of no more than 10 CFU/g. A laboratory result of “<100 CFU/g” leaves the relevant range unresolved. It does not establish either compliance or an exceedance of the 10 CFU/g criterion.

This is a reporting-capability gap. The next step is to obtain evidence capable of resolving the requirement, rather than classify the powder as contaminated from that statement alone.

A qualitative pathogen result needs a separate review. A satisfactory enumeration result does not replace a required detection test for a specified organism.

Separate Lot Sampling from the Analytical Portion

“Sample quantity” can describe several different amounts:

• Material collected from the lot.
• Material delivered to the laboratory.
• The analytical portion used for an individual test.
• The original-powder equivalent transferred to enumeration plates.

FDA’s Bacteriological Analytical Manual Chapter 1, April 2022 Edition, emphasizes representative sampling and directs laboratories to use the analytical-unit size and diluent volume appropriate to the specific method. It also recognizes that microorganisms may be distributed unevenly within a food sample.

For an incoming gum lot, establish which bags or locations were sampled and whether increments were examined separately or combined. Keep that information connected to the laboratory result.

Duplicate plates prepared from one suspension provide repeated observations of that suspension. They do not add independent samples from other bags.

Likewise, a large submitted sample does not mean the laboratory examined all of it. If a composite is used, verify that pooling and selection of the analytical portion follow the applicable plan. Its total weight alone does not establish representative coverage of the lot.

Check the Preparation Required for the Specific Gum

A material-specific preparation step can be essential to the selected method.

The historical 1999 JECFA guar gum specification provides a direct example. Its E. coli procedure includes cellulase treatment to avoid gelling when the gum is added to enrichment broth.

That example supports checking the preparation prescribed for the exact material. It does not justify adding cellulase to other methods or applying the historical procedure to every gum.

For the report under review, confirm which preparation instructions were followed. If the laboratory changed dilution, mixing, pretreatment or analytical mass, obtain the reason and its documented basis for accepting the change.

Recorded lumps, gel formation or transfer difficulties warrant technical review. Their appearance alone does not establish microbial under-recovery or a false negative. Determine whether the preparation met the method requirements before using those observations to explain a result.

Trace Dilution to the Material Represented on the Plates

At a fixed inoculation volume, additional dilution reduces the amount of original powder transferred to a plate.

Consider this illustrative mass-accounting example:

A preparation containing 0.01 g of original powder per milliliter delivers 0.01 g to an individual plate inoculated with 1 mL. One colony on that plate corresponds arithmetically to 100 CFU/g.

After a further tenfold dilution, the same inoculation volume contains 0.001 g of original powder. One colony on that individual plate corresponds to 1,000 CFU/g.

These are individual-plate equivalents. They do not independently establish a validated detection limit, quantification limit or final reporting threshold.

FDA BAM Chapter 3, January 2026 Edition, relates plate calculations to the amount of original homogenate represented in the inocula. It also provides rules for plates without colonies and results outside the stated counting range. Final calculations must follow the applicable method, including its treatment of replicate plates.

If extra dilution was needed during preparation, ask whether the completed test retained sufficient reporting capability for the agreed criterion. Obtain the laboratory’s reporting rule; do not derive a universal limit from dilution alone.

Read “No Colonies” within the Method’s Reporting Rules

An observation of no colonies requires the reporting convention of the method used.

For example, the historical 1999 JECFA xanthan gum specification describes preparation of 1 g in 99 mL of phosphate buffer, duplicate 1 mL plate inocula, and reporting of less than 100 CFU/g when no colonies are visible. This is a historical method example, rather than a current acceptance specification for every xanthan product.

The example shows why “no colonies” should not be rewritten as a measured zero. Review the preparation, inoculated amount and reporting convention together.

For qualitative testing, preserve the organism, method and analytical mass in the result statement. If a requirement specifies a particular mass, a negative result from a smaller portion does not demonstrate that the required examination was completed. It also does not predict what a larger portion would have shown.

A qualitative negative result should retain its stated scope rather than be converted into “0 CFU/g.”

Resolve Laboratory Differences before Judging Material Quality

When supplier and receiving-laboratory results disagree, check whether the tests are comparable.

Compare sample identity, analytical portion, preparation, dilution series, inoculation volume, culture medium, incubation conditions and calculation rules. Check whether yeasts and molds were reported together or separately.

FDA BAM Chapter 18, April 2001 Edition, distinguishes fungal plating approaches and includes medium-selection considerations related to sample water activity. The label “yeasts and molds” therefore does not fully identify the analytical conditions.

Where a difference affects release, request the relevant worksheets. Preparation records, colony observations and calculation details can establish whether the laboratories used different reporting thresholds or conditions.

Do not average incompatible results. Establish whether they address the same requirement first. An unresolved method difference limits comparability; it does not establish that the material deteriorated.

Match the Disposition to the Evidence

The review should distinguish a compliant result, insufficient evidence and a valid adverse result.

A reporting gap does not establish contamination. A valid exceedance requires investigation under the applicable procedure. Assess any repeat result alongside the original result and the investigation rather than automatically replacing the earlier finding.

ChemicalCell’s Thickeners category provides an entry point for identifying candidate hydrocolloid materials. Evidence for a particular food-use grade still needs to meet its agreed specification.

For the next report under review, trace one result from the sampling record through preparation to the final statement. Confirm the analytical portion, method edition and reporting capability. Use the report for release only within the microbiological requirements that this evidence actually addresses.